Please assess the completion status of the following clinical trial:

Trial Title: Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Ability to understand the purpose and risks of the study and provide signed and dated informed consent.~* Documented diagnosis of Relapsing Multiple Sclerosis (McDonald 2010 Criteria).~* Must have an Expanded Disability Status Scale (EDSS) score from 0 to 4.0, inclusive.~* Must satisfy the approved therapeutic indications for Tysabri as per Product Monograph.~* Must either be treatment naïve or have been treated with disease modifying therapy DMT(s) (such as, but not limited to, Avonex, Betaseron, Rebif, Copaxone, Extavia, Tecfidera and/or Gilenya) for ≤5 years total prior to date of informed consent.~* Decision to treat with Tysabri must precede enrollment.~Key Exclusion Criteria:~* Any prior treatment with Tysabri.~* Contraindications to treatment with Tysabri as described in the Product Monograph.~* History of progressive multifocal leukoencephalopathy (PML) or other opportunistic infections, or an increased risk for such infections.~* History of diagnosis of Primary Progressive Multiple Sclerosis \[PPMS\] and/or Secondary Progressive Multiple Sclerosis \[SPMS\].~* Receiving immunomodulatory or immunosuppressive therapy.~* Prior history of immunosuppressive use (mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate, cladribine, rituximab).~* Immunocompromised at the time of enrollment.~* Known active malignancies (subjects with cutaneous basal cell carcinoma that has been completely excised prior to study entry remain eligible).~* Women breastfeeding, pregnant, or planning to become pregnant; women who are not post-menopausal or surgically sterile who are unwilling to practice contraception.~* Inability to comply with study requirements.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).